Tafamidis (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tafamidis" in English language version.

refsWebsite

Global rank English rank

6doi.org

2^nd place

6nih.gov

4^th place

5fda.gov

447^th place

338^th place

4web.archive.org

1^st place

2tga.gov.au

3,984^th place

2,622^nd place

2europa.eu

68^th place

117^th place

2semanticscholar.org

11^th place

8^th place

2pharmatimes.com

low place

1hres.ca

low place

1canada.ca

1,712^th place

1,063^rd place

1medicines.org.uk

3,823^rd place

2,387^th place

1pmda.go.jp

6,690^th place

low place

1pfizer.com

low place

canada.ca

"Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.

doi.org

Said G, Grippon S, Kirkpatrick P (March 2012). "Tafamidis". Nature Reviews. Drug Discovery. 11 (3): 185–186. doi:10.1038/nrd3675. PMID 22378262. S2CID 256746210.
Razavi H, Palaninathan SK, Powers ET, Wiseman RL, Purkey HE, Mohamedmohaideen NN, et al. (June 2003). "Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action". Angewandte Chemie. 42 (24): 2758–2761. doi:10.1002/anie.200351179. PMID 12820260.
Jones D (November 2010). "Modifying protein misfolding". Nature Reviews. Drug Discovery. 9 (11): 825–827. doi:10.1038/nrd3316. PMID 21030987. S2CID 30702908.
Borman S (25 January 2010). "Attacking Amyloids". Chemical & Engineering News. 88 (4): 30–32. doi:10.1021/cen-v088n004.p030.
Breznitz SM, O'Shea RP, Allen TJ (March 2008). "University Commercialization Strategies in the Development of Regional Bioclusters". Journal of Product Innovation Management. 25 (2): 129–142. doi:10.1111/j.1540-5885.2008.00290.x.
Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I, et al. (26 October 2023). "World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)". Global Heart. 18 (1): 59. doi:10.5334/gh.1262. PMC 10607607. PMID 37901600.

europa.eu

ema.europa.eu

"Vyndaqel EPAR". European Medicines Agency. 16 October 2019. Retrieved 24 November 2019.
"Assessment report: Vyndaqel tafamidis meglumine Procedure No.: EMEA/H/C/002294" (PDF). EMA. 2011. Archived from the original (PDF) on 17 June 2018. Retrieved 1 April 2020. See EMA index page Archived 20 June 2018 at the Wayback Machine for updates.

fda.gov

"FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis". U.S. Food and Drug Administration. 14 September 2019. Archived from the original on 14 September 2019. Retrieved 24 November 2019. This article incorporates text from this source, which is in the public domain.
"New Drug Therapy Approvals 2019". U.S. Food and Drug Administration. 31 December 2019. Retrieved 15 September 2020.
"Drug Trial Snapshots: Vyndaqel/Vyndamax". U.S. Food and Drug Administration (FDA). 28 May 2019. Archived from the original on 19 December 2019. Retrieved 18 December 2019. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Tafamidis meglumine Orphan Drug Designation and Approval". U.S. Food and Drug Administration. 3 May 2019. Archived from the original on 19 December 2019. Retrieved 18 December 2019. This article incorporates text from this source, which is in the public domain.
"Drug Approval Package: Vyndaquel & Vyndamax". U.S. Food and Drug Administration. 13 June 2019. Retrieved 24 November 2019. This article incorporates text from this source, which is in the public domain.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Vyndaqel". Health Canada. 23 October 2014. Retrieved 29 May 2022.

medicines.org.uk

"Vyndaqel 20 mg soft capsules - Summary of Product Characteristics". Electronic Medicines Compendium. Retrieved 2 April 2018.

nih.gov

pubmed.ncbi.nlm.nih.gov

Said G, Grippon S, Kirkpatrick P (March 2012). "Tafamidis". Nature Reviews. Drug Discovery. 11 (3): 185–186. doi:10.1038/nrd3675. PMID 22378262. S2CID 256746210.
Razavi H, Palaninathan SK, Powers ET, Wiseman RL, Purkey HE, Mohamedmohaideen NN, et al. (June 2003). "Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action". Angewandte Chemie. 42 (24): 2758–2761. doi:10.1002/anie.200351179. PMID 12820260.
Jones D (November 2010). "Modifying protein misfolding". Nature Reviews. Drug Discovery. 9 (11): 825–827. doi:10.1038/nrd3316. PMID 21030987. S2CID 30702908.
Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I, et al. (26 October 2023). "World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)". Global Heart. 18 (1): 59. doi:10.5334/gh.1262. PMC 10607607. PMID 37901600.

dailymed.nlm.nih.gov

"Vyndaqel- tafamidis meglumine capsule, liquid filled Vyndamax- tafamidis capsule, liquid filled". DailyMed. 30 August 2019. Retrieved 24 November 2019.

ncbi.nlm.nih.gov

Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I, et al. (26 October 2023). "World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)". Global Heart. 18 (1): 59. doi:10.5334/gh.1262. PMC 10607607. PMID 37901600.

pfizer.com

"Pfizer's year in review". Pfizer 2023 Annual Report. 31 December 2023. Retrieved 30 December 2024.

pharmatimes.com

Grogan K (19 June 2012). "FDA rejects Pfizer rare disease drug tafamidis". Pharma Times.
"FDA rejects Pfizer rare disease drug tafamidis". PharmaTimes online. 19 June 2012. Retrieved 2 June 2021.

pmda.go.jp

"Report on the Deliberation Results" (PDF). Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare. 2 September 2013.

semanticscholar.org

api.semanticscholar.org

Said G, Grippon S, Kirkpatrick P (March 2012). "Tafamidis". Nature Reviews. Drug Discovery. 11 (3): 185–186. doi:10.1038/nrd3675. PMID 22378262. S2CID 256746210.
Jones D (November 2010). "Modifying protein misfolding". Nature Reviews. Drug Discovery. 9 (11): 825–827. doi:10.1038/nrd3316. PMID 21030987. S2CID 30702908.

tga.gov.au

"Vyndamax and Vyndaqel Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 17 July 2020. Retrieved 16 August 2020.
"AusPAR: Tafamidis and Tafamidis meglumine". Therapeutic Goods Administration. 10 September 2020. Retrieved 23 September 2020.

web.archive.org

"FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis". U.S. Food and Drug Administration. 14 September 2019. Archived from the original on 14 September 2019. Retrieved 24 November 2019. This article incorporates text from this source, which is in the public domain.
"Assessment report: Vyndaqel tafamidis meglumine Procedure No.: EMEA/H/C/002294" (PDF). EMA. 2011. Archived from the original (PDF) on 17 June 2018. Retrieved 1 April 2020. See EMA index page Archived 20 June 2018 at the Wayback Machine for updates.
"Drug Trial Snapshots: Vyndaqel/Vyndamax". U.S. Food and Drug Administration (FDA). 28 May 2019. Archived from the original on 19 December 2019. Retrieved 18 December 2019. This article incorporates text from this source, which is in the public domain.
"Tafamidis meglumine Orphan Drug Designation and Approval". U.S. Food and Drug Administration. 3 May 2019. Archived from the original on 19 December 2019. Retrieved 18 December 2019. This article incorporates text from this source, which is in the public domain.